Quest Diagnostics Incorporated (NYSE: DGX) reported first-quarter results that exceeded Wall Street expectations, with adjusted earnings of $2.50 per share beating the $2.37 consensus by 5.5%. The diagnostic testing company posted revenue of $2.90B for the quarter, up 9.2% from the $2.65B recorded in Q1 2025, as demand for laboratory services continued its robust trajectory. Net income reached $281.0M during the three-month period.
The revenue growth was driven by strong volume trends across the company’s core business. Organic requisition volume surged 10.8% for the quarter, reflecting sustained demand for diagnostic testing services. Diagnostic Information Services, the company’s largest segment, led performance with $2.83B in revenue, up 9.4% year-over-year. Quest operated with 57,000 total employees at quarter-end as it maintained capacity to handle the elevated testing volumes.
Management issued guidance for fiscal year 2026, projecting adjusted EPS in the range of $10.63 to $10.83. The company expects full-year revenue between $11.78B and $11.90B as it builds on the momentum from the first quarter. Wall Street maintains a cautiously optimistic stance on the stock, with analyst consensus standing at 7 Buy, 11 Hold, and zero Sell ratings.
A detailed analysis of Quest Diagnostics Incorporated’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post Quest Diagnostics Releases Q1 2026 Financial Results first appeared on Alphastreet.
